Bellevue Asset Management AG

Media release of November 15, 2023 Overweight and obesity are more prevalent than ever and rates are trending even higher worldwide. Compared to earlier years, though, awareness of this issue has clearly increased. Government campaigns targeting obesity reflect the heavy economic burden of this disease, in particular the indirect costs. Thanks to medical advances, such as the GLP-1 drug class, new solutions and opportunities are emerging for patients, doctors, and investors. «As a House of Healthcare Investment Ideas with more than 20 dedicated healthcare investment experts, we can offer our clients efficient access to mega trends early on. Treatments for excess weight and obesity currently benefit from strong political support, more so than in any other treatment area, and they offer attractive growth potential at the same time. The Bellevue Obesity Solutions Fund opens a completely new avenue for healthcare investors,» says Christian Lach, the fund's lead portfolio manager. The fund will be launched on November 30, 2023. New solutions for tackling the obesity pandemic
About 40% of the world’s population is overweight or obese. The WHO estimates that this figure will rise above the 50% threshold by 2035. Global costs related to obesity are forecast to rise to more than USD 4 trillion a year, which would be comparable to the impact of the COVID-19 pandemic in 2020. Solutions that reduce the prevalence of excess weight and obesity are therefore an effective means of reducing costs in healthcare systems, considering the more than 200 associated comorbidities and complications. Despite the scale and scope of this challenge, only about 2% of all affected people are receiving professional medical treatment. The numbers are alarming, but in contrast to the preceding decades, greater effort is now being made to address the issue of obesity. Organizations such as the WHO and UNICEF are calling for concerted and urgent action. Many countries have already drawn up ambitious plans to tackle this health crisis. «Medical progress has finally given us better solutions,» says co-manager Lukas Leu. «Innovative breakthroughs are largely to credit. GLP-1 drugs that help to control blood glucose levels, for example, are setting new standards for treating obesity. A holistic approach is nevertheless crucial for lasting success on this front.» The value chain is therefore much broader than one might presume. It ranges from obesity prevention, diagnostics, and treatment of obesity to the treatment of myriad related health conditions. From an investment standpoint, then, a broad-based investment vehicle for this highly compelling growth story is likely to produce the best returns. An expert portfolio built across the entire value chain
Bellevue Obesity Solutions, an actively managed and global equity fund, is exclusively focused on this mega trend. Its novel investment approach comprises healthcare sector investments (approx. 80% portfolio weighting) rounded out with investments in companies active in the fields of nutrition and physical activity (max. weighting 20%). Target companies have high sales growth, high gross margins, attractive product pipelines and a solid balance sheet. The portfolio will be constructed across the entire obesity value chain, covering the following three areas: Diagnostics and treatment: Biopharmaceutical companies focused on treating obesity and related diseases; medtech companies offering diagnostic, surgical, or monitoring and management solutions; production or distribution companies. Obesity-related diseases: Biopharma and medtech companies active in the diagnosis and treatment of obesity-related diseases, as well as healthcare services providers such as hospitals that offer a holistic approach for diabetes management, rehabilitation centers or dialysis facilities. Nutrition and physical activity: Companies active in the nutrition, fitness or sports business that are clearly relevant for obesity prevention and treatment purposes. Diversified portfolio based on bottom-up stock analysis
The portfolio management team of the Bellevue Obesity Solutions (Lux) Fund consists of Christian Lach, Lukas Leu and Oliver Kubli, all healthcare investment specialists with many years of experience. They build and manage a well-diversified but focused portfolio of 40 to 60 stocks taken from a broad universe using a fundamental bottom-up investment process.
  Contact
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht/Zurich,
Tanja Chicherio, tel. +41 44 267 67 09, tch@bellevue.ch www.bellevue.ch   Bellevue – Excellence in Specialty Investments
Bellevue is a specialized asset manager listed on the SIX Swiss Exchange with core competencies covering healthcare strategies, entrepreneur strategies, alternative and traditional investment strategies. Established in 1993, Bellevue, a House of Investment Ideas staffed by 100 professionals, generates attractive investment returns and creates value added for clients and shareholders alike. Bellevue managed CHF 8.1 bn in assets as of June 30, 2023.   Disclaimer: This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to subscribe any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. Liability for the accuracy or completeness of all information in this document is expressly disclaimed. This information does not take into account the specific or future investment objectives, the financial or tax situation or the particular needs of any specific recipient This document does not constitute independent investment research. Interested investors should always seek professional advice before making an investment decision. The information in this document is provided without any guarantees or warranties, for information purposes only, and is intended only for the personal use of the recipient. Every investment involves some risk, especially with regard to of fluctuations in value and return. Investments in foreign currency involve the additional risk that a foreign currency might lose value against an investor's reference currency. This document does not reflect all possible risk factors associated with an investment in the aforementioned securities or financial instruments. Historical performance data and financial market scenarios are no guarantee or indicator of current and future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs adversely affect performance. Financial transactions should only be carried out after thorough study of the current prospectus and are only valid on the basis of/or/and are subject to the terms given in the most recently published prospectus and annual or semi-annual report. Bellevue Funds (Lux) SICAV is admitted for public distribution in Switzerland. Representative in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zurich. Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria. Paying and information agent: Zeidler Legal Process Outsourcing Ltd., SouthPoint, Herbert House, Harmony Row, Grand Canal Dock, Dublin 2, Ireland. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany. Information agent: Zeidler Legal Process Outsourcing Ltd., SouthPoint, Herbert House, Harmony Row, Grand Canal Dock, Dublin 2, Ireland. Bellevue Funds (Lux) SICAV is registered in the CNMV registry of foreign collective investment schemes distributed in Spain, under registration number 938. Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid. Prospectus, Key Investor Information Document (“KIID”), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht. With respect to fund units distributed in or from Switzerland, the place of performance and jurisdiction is established at the registered office of the representative.